SEROCONVERSION SURVEILLANCE PROJECT

血清转换监测项目已经完成了3年半的数据 收集血友病患者艾滋病毒抗体转换率。 在125个血友病治疗中心治疗的7214名患者的数据已经被 收集和分析。30名患者被鉴定为血清转换 在此期间，其中8人符合疾病控制与预防中心的标准 凝血因子浓缩物处理后的血清转化率 清除/灭活污染病毒。八个人中没有一个是 仅使用由HIV抗体制成的浓缩物进行治疗 检测了血浆，并接受了杀死传染性病毒的治疗。对此 现在我们得出结论，艾滋病毒感染的风险来自目前可用的 由HIV抗体筛查血浆制成的浓缩物非常 很低。1990年在旧金山举行的艾滋病会议上提交了一份摘要 一份手稿正在准备中。

The Seroconversion Surveillance Project has completed 3 1\2 years of data gathering on the incidence of HIV antibody conversion in hemophiliacs. Data on 7214 patients treated at 125 Hemophilia Treatment Centers has been gathered and analyzed. Thirty patients were identified that seroconverted during this time period, and eight of them met the CDC criteria for seroconversion on clotting factor concentrates that had been treated to eliminate/inactivate contaminating viruses. None of the eight had been treated exclusively with concentrates that were made from HIV antibody tested plasma and had been treated to kill infectious viruses. At this time we conclude that the risk of HIV infection from currently available concentrates that are made from HIV antibody screened plasma is extremely low. An abstract was presented at the 1990 AIDS meeting in San Francisco and a manuscript is in preparation.